Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chinook Therapeutics Inc KDNY

Healthcare Biotechnology
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase... see more

Recent & Breaking News (NDAQ:KDNY)

Chinook Investor Alert

Newsfile May 18, 2023

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 18, 2023

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Chinook Therapeutics (KDNY) Investors with Substantial Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations

Newsfile May 18, 2023

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors

Business Wire May 18, 2023

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 17, 2023

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors

Business Wire May 17, 2023

Chinook Investor Alert

Newsfile May 17, 2023

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire May 17, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 17, 2023

The Law Offices of Frank R. Cruz Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors

Business Wire May 16, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire May 16, 2023

KDNY INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Chinook Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - KDNY

Business Wire May 16, 2023

Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease

GlobeNewswire May 16, 2023

Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates

GlobeNewswire May 9, 2023

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 5, 2023

Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress

GlobeNewswire May 5, 2023

Chinook Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire April 27, 2023

Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors

GlobeNewswire April 13, 2023

Chinook Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire April 11, 2023

Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers

GlobeNewswire April 11, 2023